证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20250826 | □ 投资者关系活动 | 特定对象调研 □ 分析师会议 | | | --- | --- | --- | | □ | 媒体采访 业绩说明会  | | | 类别 □ | 新闻发布会 □ 路演活动 | | | □ | 现场参观 其他 □ | | | 参与单位名称及 | 通过全景网"投资者关系互动平台"（网址：http://ir.p5w.net） | | | 人员姓名 | 参与公司 年半年度业绩网上说明会的投资者 2025 | | | 时间 | 年 8 月 26 日（周二）下午 15:00~17:00 | 2025 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 1、董事、总经理张海安 | | | 上市公司接待人 | 2、董事会秘书胡菁菁 | | | 员姓名 | 3、财务总监王剑 | | | | 4、独立董事刘忠海 1、董秘您好，看到上半年华邦的业绩是超出预期的，希望下半 | | | | 年能继续保持。请问公司战略有没有变化？ | | | | 投 ...

Core Viewpoint - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025, discussing its business transformation plans and financial performance [1][2]. Group 1: Meeting Details - The performance briefing took place on May 13, 2025, from 11:00 to 12:00 via the Shanghai Stock Exchange Roadshow Center [1]. - Key attendees included the Chairman, CEO, CFO, and independent directors, who engaged with investors through an interactive online format [1]. Group 2: Business Transformation and Progress - The company is focusing on deepening its industrial layout and enhancing market competitiveness, particularly in the judicial IVD sector, with plans for independent R&D and market penetration of DNA testing products [2]. - In the pharmaceutical distribution sector, the company aims to optimize hospital channel management and expand its chain franchise business [2]. - The pharmaceutical manufacturing segment will enhance operational efficiency through organizational restructuring and brand building, with a focus on core products like eye drops [2]. Group 3: Revenue Structure and Performance - The company reported a total revenue of 78.61 million for Q1 2025, with a net profit of 3.14 million, marking a turnaround from losses [9]. - The revenue contributions from different business segments for 2024 were as follows: - Pharmaceutical distribution: 182 million, down 9.34% year-on-year - Judicial IVD: 119 million, up 1.6% year-on-year - Pharmaceutical manufacturing: 35.45 million, down 20% year-on-year [5][6]. Group 4: Future Growth and Market Strategy - The company plans to continue optimizing its business structure, focusing on high-tech development and core biotechnology [8]. - Future growth will be driven by expanding into the health and judicial IVD sectors, leveraging both internal and external growth strategies [10]. - The company is also addressing potential impacts from the US-China trade war by seeking non-US suppliers and promoting domestic product alternatives [12].

Group 1 - The core viewpoint of the articles highlights the resilience and growth of the company, with a revenue of 11.665 billion yuan in 2024, maintaining over 10 billion yuan for seven consecutive years, despite intensified industry competition [2] - In the first quarter of 2025, the company achieved a nearly 20% year-on-year increase in net profit attributable to shareholders, with a gross profit margin improvement to 37.12%, indicating significant enhancement in profitability [2] - The company has made notable advancements in its pharmaceutical segment, including the approval of the first domestic generic product for psoriasis treatment, marking a significant breakthrough in the field [2] Group 2 - The medical business segment is still in the development phase, with revenue from Songshan Hospital reaching 678 million yuan in 2024, and other hospitals generating a combined revenue of 351 million yuan, showing a stable upward trend [3] - The tourism segment leverages core resources from listed company Lijiang Co. and NEEQ-listed Qinling Tourism, with operations across five major 5A scenic areas, focusing on enhancing visitor service quality and increasing tourist reception [3] - The company plans to continue executing its "big health" development strategy, concentrating on pharmaceuticals and medical services, while enhancing its full industry chain development model [3]